Insider Transactions Reported by 20 Insiders of AN2 Therapeutics, Inc.

Symbol
ANTX on Nasdaq
Location
Menlo Park, CA

Insiders trading volume in the past year

AN2 Therapeutics, Inc. executives and other stock owners filed with the SEC include:

Name Relationship Holdings Value Past Year Net Change Change % Report Date
Adjuvant Global Health Technology Fund, L.P. 10%+ Owner $45,367,317 16 Jan 2024
Braden M Leonard 10%+ Owner $3,289,000 -$3,090,477 -48% 12 Jun 2025
Paul Eckburg Chief Medical Officer $982,771 15 Mar 2024
Joseph S. Zakrzewski Director $739,451 20 Feb 2026
Eric Easom Chief Executive Officer, Director $614,707 +$10,665 +1.8% 20 Feb 2026
Kevin Michael Krause Chief Strategy Officer $610,007 15 Mar 2024
Kabeer Aziz Director $498,823 20 Feb 2026
RA CAPITAL MANAGEMENT, L.P. 10%+ Owner $324,921 09 Aug 2024
Joshua M. Eizen Chief Operating Officer and Chief Legal Officer $273,898 -$28,176 -9.3% 20 Feb 2026
Sanjay Chanda Chief Development Officer $156,846 -$9,332 -5.6% 20 Feb 2026
Lucy Day Chief Financial Officer $156,239 -$8,883 -5.4% 20 Feb 2026
Gilbert Lynn Marks Director $87,358 20 Feb 2026
Sarah Joanne Williams Principal Accounting Officer $70,858 -$347 -0.49% 03 Mar 2026
Stephen David Prior Chief Strategy Officer $59,795 -$7,379 -11% 05 Jan 2026
Patricia A. Martin Director $19,609 20 Feb 2026
Margaret M. FitzPatrick Director $10,133 +$10,133 20 Feb 2026
Robin Shane Readnour Director 20 Feb 2026
Stephanie Wong Director 20 Feb 2026
Melvin K. Spigelman Director 20 Feb 2026
Michael Adrian Nazak Chief Accounting Officer 15 Feb 2023

Recent Insider Transactions by Companies or Individuals for AN2 Therapeutics, Inc.

Insider Symbol Class Transaction % Value $ * Price $ Shares Shares Owned Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.